BioSyent Inc.

TSXV:RX Stock Report

Market Cap: CA$128.5m

BioSyent Management

Management criteria checks 3/4

BioSyent's CEO is René Goehrum, appointed in May 1999, has a tenure of 25.67 years. total yearly compensation is CA$747.51K, comprised of 47.7% salary and 52.3% bonuses, including company stock and options. directly owns 8.78% of the company’s shares, worth CA$11.28M. The average tenure of the management team and the board of directors is 6.3 years and 9 years respectively.

Key information

René Goehrum

Chief executive officer

CA$747.5k

Total compensation

CEO salary percentage47.7%
CEO tenure25.7yrs
CEO ownership8.8%
Management average tenure6.3yrs
Board average tenure9yrs

Recent management updates

Did BioSyent Inc. (CVE:RX) Insiders Buy Up More Shares?

Dec 02
Did BioSyent Inc. (CVE:RX) Insiders Buy Up More Shares?

Recent updates

BioSyent (CVE:RX) Is Paying Out A Dividend Of CA$0.045

Nov 23
BioSyent (CVE:RX) Is Paying Out A Dividend Of CA$0.045

BioSyent's (CVE:RX) Dividend Will Be CA$0.045

Aug 30
BioSyent's (CVE:RX) Dividend Will Be CA$0.045

BioSyent's (CVE:RX) Profits May Not Reveal Underlying Issues

Mar 22
BioSyent's (CVE:RX) Profits May Not Reveal Underlying Issues

BioSyent (CVE:RX) Will Pay A Larger Dividend Than Last Year At CA$0.045

Feb 09
BioSyent (CVE:RX) Will Pay A Larger Dividend Than Last Year At CA$0.045

BioSyent Inc.'s (CVE:RX) Intrinsic Value Is Potentially 38% Above Its Share Price

Apr 14
BioSyent Inc.'s (CVE:RX) Intrinsic Value Is Potentially 38% Above Its Share Price

BioSyent Inc. (CVE:RX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Mar 19
BioSyent Inc. (CVE:RX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Declining Stock and Solid Fundamentals: Is The Market Wrong About BioSyent Inc. (CVE:RX)?

Mar 17
Declining Stock and Solid Fundamentals: Is The Market Wrong About BioSyent Inc. (CVE:RX)?

BioSyent (CVE:RX) Shareholders Booked A 33% Gain In The Last Year

Feb 18
BioSyent (CVE:RX) Shareholders Booked A 33% Gain In The Last Year

Here's Why BioSyent's (CVE:RX) Statutory Earnings Are Arguably Too Conservative

Jan 28
Here's Why BioSyent's (CVE:RX) Statutory Earnings Are Arguably Too Conservative

BioSyent Inc. (CVE:RX) Shares Could Be 30% Below Their Intrinsic Value Estimate

Jan 07
BioSyent Inc. (CVE:RX) Shares Could Be 30% Below Their Intrinsic Value Estimate

BioSyent Inc.'s (CVE:RX) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Dec 17
BioSyent Inc.'s (CVE:RX) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Did BioSyent Inc. (CVE:RX) Insiders Buy Up More Shares?

Dec 02
Did BioSyent Inc. (CVE:RX) Insiders Buy Up More Shares?

CEO Compensation Analysis

How has René Goehrum's remuneration changed compared to BioSyent's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

CA$7m

Jun 30 2024n/an/a

CA$7m

Mar 31 2024n/an/a

CA$7m

Dec 31 2023CA$748kCA$357k

CA$6m

Sep 30 2023n/an/a

CA$6m

Jun 30 2023n/an/a

CA$5m

Mar 31 2023n/an/a

CA$5m

Dec 31 2022CA$681kCA$343k

CA$5m

Sep 30 2022n/an/a

CA$6m

Jun 30 2022n/an/a

CA$6m

Mar 31 2022n/an/a

CA$6m

Dec 31 2021CA$681kCA$329k

CA$6m

Sep 30 2021n/an/a

CA$5m

Jun 30 2021n/an/a

CA$4m

Mar 31 2021n/an/a

CA$4m

Dec 31 2020CA$649kCA$325k

CA$4m

Sep 30 2020n/an/a

CA$4m

Jun 30 2020n/an/a

CA$5m

Mar 31 2020n/an/a

CA$5m

Dec 31 2019CA$497kCA$310k

CA$4m

Sep 30 2019n/an/a

CA$5m

Jun 30 2019n/an/a

CA$5m

Mar 31 2019n/an/a

CA$6m

Dec 31 2018CA$528kCA$300k

CA$6m

Compensation vs Market: René's total compensation ($USD521.36K) is above average for companies of similar size in the Canadian market ($USD164.59K).

Compensation vs Earnings: René's compensation has been consistent with company performance over the past year.

CEO

René Goehrum (65 yo)

25.7yrs

Tenure

CA$747,509

Compensation

Mr. René C. Goehrum has been the Chairman of BioSyent Inc. since June 1999 and its Chief Executive Officer since May 1999 and also its President since June 2006. Mr. Goehrum served as the President and ser...

Leadership Team

NamePositionTenureCompensationOwnership
René Goehrum
Chairman25.7yrsCA$747.51k8.78%
CA$ 11.3m
Robert March
VP of Finance & CFO6.3yrsCA$340.38k0.49%
CA$ 635.8k
Kevin Wilson
Vice President of Salesless than a yearCA$255.09k0.57%
CA$ 732.2k
Joost van der Mark
Vice President of Corporate Development6.3yrsCA$315.75k0.46%
CA$ 596.0k
Neelu Atwal
Director of Human Resources6yrsno data0.18%
CA$ 228.0k

6.3yrs

Average Tenure

Experienced Management: RX's management team is seasoned and experienced (6.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
René Goehrum
Chairman29yrsCA$747.51k8.78%
CA$ 11.3m
Joseph Arcuri
Independent Director6.7yrsCA$43.04k0.10%
CA$ 132.9k
Larry Andrews
Independent Director7yrsCA$39.98k0.085%
CA$ 109.4k
Peter Lockhard
Lead Independent Director22.6yrsCA$42.25k1.59%
CA$ 2.0m
Sara Elford
Independent Director7yrsCA$39.00k0.13%
CA$ 171.2k
Stephen Wilton
Independent Director11yrsCA$39.00k0.028%
CA$ 35.7k

9.0yrs

Average Tenure

62.5yo

Average Age

Experienced Board: RX's board of directors are considered experienced (9 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/21 05:53
End of Day Share Price 2025/01/21 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

BioSyent Inc. is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David MartinBloom Burton & Co.
Scott CurtisCantor Fitzgerald Canada Corporation
Tania Armstrong-WhitworthCormark Securities Inc.